Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02303457
Other study ID # 2014012
Secondary ID
Status Recruiting
Phase N/A
First received November 2, 2014
Last updated January 27, 2016
Start date July 2014
Est. completion date July 2024

Study information

Verified date January 2016
Source Sun Yat-sen University
Contact xuekui liu, doctor
Phone (86-20) 8734 3768
Email liuxk@sysucc.org.cn
Is FDA regulated No
Health authority China: Health and Family Planning Commission of Guangdong Province
Study type Interventional

Clinical Trial Summary

Open surgery and CO2 laser surgery are both established treatment modalities for T1N0 glottic carcinoma. It is controversial for T1N0 glottic carcinoma with anterior commissure involved.


Recruitment information / eligibility

Status Recruiting
Enrollment 402
Est. completion date July 2024
Est. primary completion date July 2024
Accepts healthy volunteers No
Gender Both
Age group 20 Years to 70 Years
Eligibility Inclusion Criteria:

- T1N0 SCC of glottic carcinoma with anterior commissure involve

- No nodal metastasis and distant metastasis

- All patients must have CT/MR and electronic laryngoscope test before surgery and after surgery

- Expected lifetime>1 year

- Patients and families agreed to participate in the test and sign the informed consent

- Without cognitive impairment.

Exclusion Criteria:

- With severe cardiac insufficiency Liver and kidney function is not complete systemic infection patients

- Patients with pregnancy and lactation

- Have surgery contraindications

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Procedure:
CO2 Laser surgery
Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
Open Surgery
Patients were randomly assigned to CO2 laser surgery group and open Surgery group.

Locations

Country Name City State
China Sun Yat-sen University Cancer Center Guangzhou Guangdong

Sponsors (4)

Lead Sponsor Collaborator
Xuekui Liu First Affiliated Hospital, Sun Yat-Sen University, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Third Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary disease-free survival 5 years No
Secondary recurrence rate 5 years No